Repotractinib克服ROS1重排非小细胞肺癌癌症中F2004V耐药性突变的病例报告

IF 3 Q2 ONCOLOGY
Elio Gregory Pizzutilo MD , Alberto Giuseppe Agostara MD , Laura Roazzi MD , Rebecca Romanò MD , Valentina Motta PhD , Calogero Lauricella PhD , Giovanna Marrapese PhD , Giulio Cerea MD , Diego Signorelli MD, PhD , Silvio Marco Veronese PhD , Laura Giuseppina Giannetta MD , Andrea Sartore-Bianchi MD , Salvatore Siena MD
{"title":"Repotractinib克服ROS1重排非小细胞肺癌癌症中F2004V耐药性突变的病例报告","authors":"Elio Gregory Pizzutilo MD ,&nbsp;Alberto Giuseppe Agostara MD ,&nbsp;Laura Roazzi MD ,&nbsp;Rebecca Romanò MD ,&nbsp;Valentina Motta PhD ,&nbsp;Calogero Lauricella PhD ,&nbsp;Giovanna Marrapese PhD ,&nbsp;Giulio Cerea MD ,&nbsp;Diego Signorelli MD, PhD ,&nbsp;Silvio Marco Veronese PhD ,&nbsp;Laura Giuseppina Giannetta MD ,&nbsp;Andrea Sartore-Bianchi MD ,&nbsp;Salvatore Siena MD","doi":"10.1016/j.jtocrr.2023.100555","DOIUrl":null,"url":null,"abstract":"<div><p>ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged responses. For this reason, next-generation compounds are under clinical development. ROS1 F2004 substitutions have been previously detected on circulating tumor DNA of patients progressing to entrectinib. Hereby, we report the case of a patient with ROS1+ NSCLC in which F2004V-acquired mutation was detected on a site of disease progression, after entrectinib and crizotinib failure. A subsequent treatment with next-generation TKI repotrectinib led to disease response, providing the first clinical evidence of activity of repotrectinib against F2004V resistance mutation.</p></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266636432300098X/pdfft?md5=cb2e257dc0f7c9a2548efebc9427216f&pid=1-s2.0-S266636432300098X-main.pdf","citationCount":"1","resultStr":"{\"title\":\"Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report\",\"authors\":\"Elio Gregory Pizzutilo MD ,&nbsp;Alberto Giuseppe Agostara MD ,&nbsp;Laura Roazzi MD ,&nbsp;Rebecca Romanò MD ,&nbsp;Valentina Motta PhD ,&nbsp;Calogero Lauricella PhD ,&nbsp;Giovanna Marrapese PhD ,&nbsp;Giulio Cerea MD ,&nbsp;Diego Signorelli MD, PhD ,&nbsp;Silvio Marco Veronese PhD ,&nbsp;Laura Giuseppina Giannetta MD ,&nbsp;Andrea Sartore-Bianchi MD ,&nbsp;Salvatore Siena MD\",\"doi\":\"10.1016/j.jtocrr.2023.100555\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged responses. For this reason, next-generation compounds are under clinical development. ROS1 F2004 substitutions have been previously detected on circulating tumor DNA of patients progressing to entrectinib. Hereby, we report the case of a patient with ROS1+ NSCLC in which F2004V-acquired mutation was detected on a site of disease progression, after entrectinib and crizotinib failure. A subsequent treatment with next-generation TKI repotrectinib led to disease response, providing the first clinical evidence of activity of repotrectinib against F2004V resistance mutation.</p></div>\",\"PeriodicalId\":17675,\"journal\":{\"name\":\"JTO Clinical and Research Reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2023-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S266636432300098X/pdfft?md5=cb2e257dc0f7c9a2548efebc9427216f&pid=1-s2.0-S266636432300098X-main.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JTO Clinical and Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S266636432300098X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S266636432300098X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

摘要

ROS1酪氨酸激酶抑制剂(TKIs)被发现为晚期ROS1阳性(ROS1+) NSCLC患者提供了实质性的临床益处。然而,TKI耐药性不可避免地以不同的机制发展,防止长期反应。因此,新一代化合物正在进行临床开发。ROS1 F2004替代先前已在进展为肠替尼的患者的循环肿瘤DNA中检测到。在此,我们报告了一例ROS1+ NSCLC患者,在enterrectinib和crizotinib失效后,在疾病进展部位检测到f2004v获得性突变。随后使用下一代TKI repotrectinib治疗导致疾病缓解,提供了repotrectinib抗F2004V耐药突变活性的第一个临床证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Repotrectinib Overcomes F2004V Resistance Mutation in ROS1-Rearranged NSCLC: A Case Report

ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged responses. For this reason, next-generation compounds are under clinical development. ROS1 F2004 substitutions have been previously detected on circulating tumor DNA of patients progressing to entrectinib. Hereby, we report the case of a patient with ROS1+ NSCLC in which F2004V-acquired mutation was detected on a site of disease progression, after entrectinib and crizotinib failure. A subsequent treatment with next-generation TKI repotrectinib led to disease response, providing the first clinical evidence of activity of repotrectinib against F2004V resistance mutation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.20
自引率
0.00%
发文量
145
审稿时长
19 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信